세계의 세포 및 유전자 치료제 제조 서비스 시장 보고서(2025년)
Cell & Gene Therapy Manufacturing Services Global Market Report 2025
상품코드 : 1821722
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세포 및 유전자 치료제 제조 서비스 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에 179억 2,000만 달러로 성장할 것으로 예측되고 CAGR은 17.4%입니다. 예측 기간 동안의 성장은 시장 성숙 및 상용화, 전 세계의 바이오의약품 제조의 확장, 제약사의 아웃소싱 증가, 자동화 및 로봇공학 발전, 새로운 치료제 모달리티의 출현에 기인할 수 있습니다. 예측 기간의 주요 동향으로는 에너지 효율성, 첨단 소재 및 기술, 컴팩트하고 모듈식 설계, 교통 수단의 전기화, 안전성과 신뢰성에 대한 주력 등이 포함됩니다.

향후 5년간 17.4% 성장 전망은 이전 예측 대비 0.1% 소폭 하향 조정된 수치입니다. 이 같은 하향 조정은 주로 미국과 타국 간 관세 영향 때문입니다. 관세 부과로 인해 프랑스 및 싱가포르에서 수입되는 바이러스 벡터 생산 및 세포 처리 서비스 비용이 증가하여 미국 첨단 치료제 공급에 차질이 발생할 수 있으며, 이는 생명 구제 치료제 접근성 저하와 생산 비용 15-20% 상승으로 이어질 수 있습니다. 상호 관세 부과와 무역 긴장 및 제한 강화로 인한 전 세계 경제 및 무역에 대한 부정적 영향으로 그 효과는 더욱 광범위하게 나타날 것입니다.

세포 및 유전자 치료제 제조 서비스 시장은 암과 같은 질병의 증가로 인해 성장을 경험할 것으로 예상됩니다. 암의 빠르고 통제되지 않은 세포 증식은 더 효과적인 치료법에 대한 수요 급증을 초래하여 세포 및 유전자 치료법 개발을 촉진하고 있습니다. 예를 들어, 2023년 1월 미국 암 협회는 2021년부터 2023년에 걸쳐 암 환자가 3.16% 증가한다고 보고하고 있으며, 이러한 동향을 해결하기 위한 혁신적 치료법의 필요성이 커지고 있음을 강조했습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

HBR
영문 목차

영문목차

Cell and gene therapy manufacturing services encompass processes dedicated to manufacturing and ensuring the quality of gene and cell therapy products. These services play a pivotal role in developing treatments for degenerative conditions, tissue injuries, and genetic abnormalities. They involve adhering to good manufacturing practices, utilizing ancillary reagents, conducting flow cytometry and immunoassays, and offering gene engineering services.

The primary types of these manufacturing services include gene therapy and cell therapy. Gene therapy involves addressing underlying genetic issues to treat or prevent diseases. These services cater to both commercial manufacturing and clinical applications, targeting diverse medical indications such as central nervous system disorders, ophthalmology diseases, cardiovascular diseases, infectious diseases, orthopedic diseases, and oncology diseases. These specialized services are utilized by academic and research institutes, pharmaceutical and biotechnology companies, and other relevant entities involved in the development and production of cell and gene therapies aimed at addressing various medical conditions.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The cell and gene therapy manufacturing services market research report is one of a series of new reports from The Business Research Company that provides cell and gene therapy manufacturing services optical components market statistics, including cell and gene therapy manufacturing services optical components industry global market size, regional shares, competitors with a cell and gene therapy manufacturing services optical components market share, detailed cell and gene therapy manufacturing services optical components market segments, market trends and opportunities, and any further data you may need to thrive in the cell and gene therapy manufacturing services optical components industry. This cell and gene therapy manufacturing services optical components market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cell & gene therapy manufacturing services market size has grown rapidly in recent years. It will grow from $8.15 billion in 2024 to $9.44 billion in 2025 at a compound annual growth rate (CAGR) of 15.9%. The growth in the historic period can be attributed to increased R&D investments, regulatory support and frameworks, growing pipeline of cell & gene therapies, industry collaborations and partnerships, increasing global demand for personalized medicine.

The cell & gene therapy manufacturing services market size is expected to see rapid growth in the next few years. It will grow to $17.92 billion in 2029 at a compound annual growth rate (CAGR) of 17.4%. The growth in the forecast period can be attributed to market maturation and commercialization, global expansion of biopharmaceutical manufacturing, increased outsourcing by pharma companies, advancements in automation and robotics, emergence of new therapeutic modalities. Major trends in the forecast period include rising demand for energy efficiency, advanced materials and technologies, compact and modular designs, electrification of transportation, focus on safety and reliability.

The forecast of 17.4% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. advanced therapies by increasing costs for viral vector production and cell processing services imported from France and Singapore, potentially slowing life-saving treatment availability and raising production costs by 15-20%. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The cell and gene therapy manufacturing services market is anticipated to experience growth due to the increasing prevalence of diseases such as cancer. Cancer's rapid and uncontrolled cell growth has led to a surge in demand for more effective treatments, spurring the development of cell and gene therapies. For example, in January 2023, the American Cancer Society reported a 3.16% increase in cancer cases from 2021 to 2023, highlighting the escalating need for innovative therapies to address this trend.

The market for cell and gene therapy manufacturing services is expected to expand further owing to the rising adoption of personalized medicine. This approach tailors medical treatments to individual patient characteristics, significantly enhancing the efficacy of cell and gene therapies. Notably, in January 2023, the FDA's Center for Drug Evaluation and Research approved 37 new molecular entities in 2022, with 12 of them classified as personalized medicines by the Personalized Medicine Coalition (PMC), signifying the growing prominence of personalized treatments.

Technological advancements are driving trends in the cell and gene therapy manufacturing services market. Companies are embracing innovative technologies to maintain their market positions. For instance, in October 2022, Charles River Laboratories International Inc. introduced the navigation Vector Platform, simplifying GMP Adeno-Associated Virus (AAV) vector manufacturing. This platform drastically reduces the time required for viral vector gene therapy researchers compared to conventional workflows, enhancing efficiency and scalability.

Collaborations and partnerships among key players are reshaping the cell and gene therapy manufacturing services market, fostering innovation and accelerating product development. An instance is the collaboration between Allogene Therapeutics Inc. and Antion Biosciences SA to advance multiplex gene silencing for developing next-generation allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer.

In June 2024, Genezen, a gene and cell therapy company based in the United States, acquired UniQure for an undisclosed sum. This acquisition is intended to bolster Genezen's capabilities in gene therapy production, broaden its range of services, and utilize UniQure's expertise to address the increasing demand for innovative gene therapies in the market. UniQure is a biotechnology company located in the Netherlands that focuses on gene therapies for severe diseases.

Major companies operating in the cell & gene therapy manufacturing services market include Thermo Fisher Scientific Inc., Merck KGaA, Charles River Laboratories International Inc., Lonza Group AG, Catalent Inc., WuXi AppTec, Takara Bio Inc., Nikon Corporation, Fujifilm Holdings Corporation, F. Hoffmann-La Roche Ltd, Oxford Biomedica plc, CGT Catapult, bluebird bio Inc., Boehringer Ingelheim International GmbH, Innovative Cellular Therapeutics Co. Ltd., Samsung Biologics Co. Ltd., Novartis International AG, Pfizer Inc., Brammer Bio, AGC Biologics, Cognate BioServices Inc., Paragon Bioservices Inc., Merck KGaA operating as MilliporeSigma, Sarepta Therapeutics Inc., Spark Therapeutics Inc., Orchard Therapeutics plc, Precision BioSciences Inc., PCT a Hitachi Group Company, Aldevron LLC, BioNTech SE

North America was the largest region in the cell and gene therapy manufacturing services market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global cell & gene therapy manufacturing services market report forecast period. The regions covered in the cell & gene therapy manufacturing services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the cell & gene therapy manufacturing services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The cell and gene therapy manufacturing services market includes revenues earned by cell and gene therapy manufacturing and related services which include analytical and process development, current good manufacturing practice cell therapy manufacturing services of autologous and allogeneic t-cells, natural killer cells, dendritic cells, mesenchymal stem cells, hematopoietic stem cells, and more. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cell & Gene Therapy Manufacturing Services Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cell & gene therapy manufacturing services market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for cell & gene therapy manufacturing services ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cell & gene therapy manufacturing services market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Cell & Gene Therapy Manufacturing Services Market Characteristics

3. Cell & Gene Therapy Manufacturing Services Market Trends And Strategies

4. Cell & Gene Therapy Manufacturing Services Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Cell & Gene Therapy Manufacturing Services Growth Analysis And Strategic Analysis Framework

6. Cell & Gene Therapy Manufacturing Services Market Segmentation

7. Cell & Gene Therapy Manufacturing Services Market Regional And Country Analysis

8. Asia-Pacific Cell & Gene Therapy Manufacturing Services Market

9. China Cell & Gene Therapy Manufacturing Services Market

10. India Cell & Gene Therapy Manufacturing Services Market

11. Japan Cell & Gene Therapy Manufacturing Services Market

12. Australia Cell & Gene Therapy Manufacturing Services Market

13. Indonesia Cell & Gene Therapy Manufacturing Services Market

14. South Korea Cell & Gene Therapy Manufacturing Services Market

15. Western Europe Cell & Gene Therapy Manufacturing Services Market

16. UK Cell & Gene Therapy Manufacturing Services Market

17. Germany Cell & Gene Therapy Manufacturing Services Market

18. France Cell & Gene Therapy Manufacturing Services Market

19. Italy Cell & Gene Therapy Manufacturing Services Market

20. Spain Cell & Gene Therapy Manufacturing Services Market

21. Eastern Europe Cell & Gene Therapy Manufacturing Services Market

22. Russia Cell & Gene Therapy Manufacturing Services Market

23. North America Cell & Gene Therapy Manufacturing Services Market

24. USA Cell & Gene Therapy Manufacturing Services Market

25. Canada Cell & Gene Therapy Manufacturing Services Market

26. South America Cell & Gene Therapy Manufacturing Services Market

27. Brazil Cell & Gene Therapy Manufacturing Services Market

28. Middle East Cell & Gene Therapy Manufacturing Services Market

29. Africa Cell & Gene Therapy Manufacturing Services Market

30. Cell & Gene Therapy Manufacturing Services Market Competitive Landscape And Company Profiles

31. Cell & Gene Therapy Manufacturing Services Market Other Major And Innovative Companies

32. Global Cell & Gene Therapy Manufacturing Services Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cell & Gene Therapy Manufacturing Services Market

34. Recent Developments In The Cell & Gene Therapy Manufacturing Services Market

35. Cell & Gene Therapy Manufacturing Services Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기